Rheumatoid Arthritis Clinical Trial
Official title:
Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial
Bi Syndrome is one of Traditional Chinese Medicine(TCM)name, It means an obstruction in Chinese,and it refers the syndrome characterized by the obstruction of qi and blood in the meridians due to the invasion of external pathogenic wind,cold and dampness, manifested as soreness, pain, numb,etc. Bi Syndrome contains Rheumatoid arthritis(RA). RA is a chronic disease affecting more than 20 million people in the world.It is one of the most common forms of autoimmune disease. Xin'an Medicine is one of Traditional Chinese Medicine which originated from AnHui. Xinfeng Capsule developed according to the Xin'an medicine theory ,and it has long been adopted for treatment of rheumatoid arthritis (RA). The study is aimed to evaluate the effectiveness and safety of Xinfeng Capsule in the treatment of RA.
Status | Completed |
Enrollment | 304 |
Est. completion date | August 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria. - According with the Zheng diagnosis of Traditional Chinese Medicine. - age from 18 to 65 years. - For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs): Treatment at a stable dose during last 4 weeks prior to screening,or Patients do not take NSAIDs at least 1 weeks prior to screening. - Patients not taking DMARDs at least 4 weeks prior to screening. - Patients taking corticosteroids (=15mg prednisone or Equivalent) =4 weeks before entering the trial. - Patients agree to participate in this study and sign the informed consent form. Exclusion Criteria: - Patients have received intra-articular or systemic corticosteroid injection within 4 weeks of screening. - Patients have high disease activity (DAS28-3 scores> 5.1). - Patients have diagnosed any other chronic inflammatory disease or connective tissue disease like sicca syndrome(SS), systemic lupus erythematosus (SLE)etc; - Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and hematopoietic system ; - Patients who are pregnant or nursing mothers or Psychiatric patients. - Patients with active gastroduodenal ulcer or gastritis which caused by long-term use of NSAIDs; - The patient who has known hypersensitivity to trial medicine . - Patients have participated in other clinical trials within 4 weeks of screening. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | The first affiliated hospital of bengbu medical college | Bengbu | Anhui |
China | The first affiliated hospital of anhui medical university | Hefei | Anhui |
China | Yijishan Hospital of Wannan Medical College | Wuhu | Anhui |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Ministry of Science and Technology of the People´s Republic of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ACR20 (American College of Rheumatology (ACR) criteria of 20% improvement in symptoms ) | ACR20 used for evaluating the efficacy of rheumatoid arthritis (RA). | baseline,week4,week8,week12 | No |
Secondary | ACR50 (American College of Rheumatology (ACR) criteria of 50% improvement in symptoms ) | ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA). | baseline,week4,week8,week12 | No |
Secondary | ACR70 (American College of Rheumatology (ACR) criteria of 70% improvement in symptoms ) | ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA). | baseline,week4,week8,week12 | No |
Secondary | Patterns based on Chinese medicine(CM)symptoms | baseline,week4,week8,week12 | No | |
Secondary | Disease Activity Scale (DAS)28 | baseline,week4,week8, week12 | No | |
Secondary | Rheumatoid arthritis (RA) biomarkers | Rheumatoid arthritis (RA) biomarkers,including rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) ,anti-cyclic citrullinated peptide (anti-CCP) antibodies, IgG?IgA?IgM, d-dimer, the coagulation function tests | baseline, week12 | Yes |
Secondary | Life Quality Assessment | Life Quality Assessment,including Health Assessment Questionnaire (HAQ), Self-rating depression scale(SDS), Self-rating anxiety scale(SAS),quality of life Questionnaire with rheumatoid arthritis. | baseline,week12 | No |
Secondary | x-rays of the hands and wrists | baseline,week12 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |